• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Infections and the risk of incident giant cell arteritis: a population-based, case-control study
Conclusions Antecedent infections and, to a lesser extent, herpes zoster infections are modestly associated with incident GCA. These data provide population-level support for the hypothesis that long-standing alterations of the immune system are associated with susceptibility to GCA and suggest that herpes zoster is unlikely to play a major causal role in the pathogenesis of GCA.
Source: Annals of the Rheumatic Diseases - May 13, 2017 Category: Rheumatology Authors: Rhee, R. L., Grayson, P. C., Merkel, P. A., Tomasson, G. Tags: Immunology (including allergy), Vascularitis, Epidemiology Clinical and epidemiological research Source Type: research

Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis
Conclusions The rate of zoster associated with tofacitinib was approximately double that observed in patients using biologics.
Source: Annals of the Rheumatic Diseases - September 8, 2016 Category: Rheumatology Authors: Curtis, J. R., Xie, F., Yun, H., Bernatsky, S., Winthrop, K. L. Tags: Immunology (including allergy), Connective tissue disease, Degenerative joint disease, Musculoskeletal syndromes, Rheumatoid arthritis Clinical and epidemiological research Source Type: research

Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biological disease-modifying antirheumatic drugs
Conclusions Tofacitinib demonstrated efficacy in both bDMARD-naive and bDMARD-IR patients with RA. Clinical response to tofacitinib was generally numerically greater in bDMARD-naive than bDMARD-IR patients. The safety profile appeared similar between subpopulations. Trial registration numbers (NCT00413660, NCT0050446, NCT00603512, NCT00687193, NCT00960440, NCT00847613, NCT00814307, NCT00856544, NCT00853385).
Source: Annals of the Rheumatic Diseases - June 9, 2016 Category: Rheumatology Authors: Charles-Schoeman, C., Burmester, G., Nash, P., Zerbini, C. A. F., Soma, K., Kwok, K., Hendrikx, T., Bananis, E., Fleischmann, R. Tags: Open access, Immunology (including allergy), Biological agents, Connective tissue disease, Degenerative joint disease, Drugs: musculoskeletal and joint diseases, Musculoskeletal syndromes, Rheumatoid arthritis Clinical and epidemiological research Source Type: research

Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis
Conclusions Within the global tofacitinib RA development programme, TB was the most common OI reported but was rare in regions of low and medium TB incidence. Patients who screen positive for latent TB can be treated with isoniazid during tofacitinib therapy.
Source: Annals of the Rheumatic Diseases - May 9, 2016 Category: Rheumatology Authors: Winthrop, K. L., Park, S.-H., Gul, A., Cardiel, M. H., Gomez-Reino, J. J., Tanaka, Y., Kwok, K., Lukic, T., Mortensen, E., Ponce de Leon, D., Riese, R., Valdez, H. Tags: Open access, Immunology (including allergy), Connective tissue disease, Degenerative joint disease, Musculoskeletal syndromes, Rheumatoid arthritis Clinical and epidemiological research Source Type: research

Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study
Conclusions Treatment with peficitinib as monotherapy for 12 weeks in Japanese patients with moderate to severe RA is efficacious and showed acceptable safety profile. These findings support further developments of peficitinib for RA treatment. Trial registration number NCT01649999; Results.
Source: Annals of the Rheumatic Diseases - May 9, 2016 Category: Rheumatology Authors: Takeuchi, T., Tanaka, Y., Iwasaki, M., Ishikura, H., Saeki, S., Kaneko, Y. Tags: Open access, Immunology (including allergy), Biological agents, Connective tissue disease, Degenerative joint disease, Drugs: musculoskeletal and joint diseases, Musculoskeletal syndromes, Rheumatoid arthritis Clinical and epidemiological research Source Type: research

Psoriatic arthritis treatment and the risk of herpes zoster
Conclusions In our database, the risk of HZ was significantly increased with age, treatment with steroids, and combination of anti-TNF-α agents and c-DMARDs, but not with c-DMARDs or anti-TNF-α therapy alone. Time to HZ event was shorter in patients treated with anti -TNF-α agents.
Source: Annals of the Rheumatic Diseases - December 11, 2015 Category: Rheumatology Authors: Zisman, D., Bitterman, H., Shalom, G., Feldhamer, I., Comanesther, D., Batat, E., Greenberg-Dotan, S., Cohen, S., Cohen, A. D. Tags: Immunology (including allergy), Biological agents, Connective tissue disease, Degenerative joint disease, Drugs: musculoskeletal and joint diseases, Musculoskeletal syndromes, Rheumatoid arthritis, Epidemiology Clinical and epidemiological research Source Type: research

Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate
Conclusions Baricitinib improved the signs and symptoms of RA in methotrexate inadequate responders with active disease. Baricitinib was well tolerated with no unexpected safety findings through week 24. Trial registration number NCT01185353.
Source: Annals of the Rheumatic Diseases - January 7, 2015 Category: Rheumatology Authors: Keystone, E. C., Taylor, P. C., Drescher, E., Schlichting, D. E., Beattie, S. D., Berclaz, P.-Y., Lee, C. H., Fidelus-Gort, R. K., Luchi, M. E., Rooney, T. P., Macias, W. L., Genovese, M. C. Tags: Open access, Immunology (including allergy), Connective tissue disease, Degenerative joint disease, Musculoskeletal syndromes, Rheumatoid arthritis Clinical and epidemiological research Source Type: research

Efficacy and safety of open-label etanercept on extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis and psoriatic arthritis: part 1 (week 12) of the CLIPPER study
Conclusions ETN treatment for 12 weeks was effective and well tolerated in paediatric subjects with eoJIA, ERA and PsA, with no unexpected safety findings.
Source: Annals of the Rheumatic Diseases - April 30, 2014 Category: Rheumatology Authors: Horneff, G., Burgos-Vargas, R., Constantin, T., Foeldvari, I., Vojinovic, J., Chasnyk, V. G., Dehoorne, J., Panaviene, V., Susic, G., Stanevica, V., Kobusinska, K., Zuber, Z., Mouy, R., Rumba-Rozenfelde, I., Breda, L., Dolezalova, P., Job-Deslandre, C., W Tags: Open access, Immunology (including allergy), Pain (neurology), Renal medicine, Connective tissue disease, Degenerative joint disease, Musculoskeletal syndromes, Rheumatoid arthritis Clinical and epidemiological research Source Type: research

Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis
Conclusions The findings from this SLR confirm the known safety pattern of sDMARDs and bDMARDs for the treatment of RA.
Source: Annals of the Rheumatic Diseases - February 4, 2014 Category: Rheumatology Authors: Ramiro, S., Gaujoux-Viala, C., Nam, J. L., Smolen, J. S., Buch, M., Gossec, L., van der Heijde, D., Winthrop, K., Landewe, R. Tags: Immunology (including allergy), Biological agents, Connective tissue disease, Degenerative joint disease, Drugs: musculoskeletal and joint diseases, Musculoskeletal syndromes, Rheumatoid arthritis Clinical and epidemiological research Source Type: research